Compare GDHG & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDHG | QTTB |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 44.3M |
| IPO Year | 2023 | N/A |
| Metric | GDHG | QTTB |
|---|---|---|
| Price | $1.91 | $3.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 7.1K | ★ 179.9K |
| Earning Date | 07-11-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,288,195.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.82 | $1.35 |
| 52 Week High | $1,968.41 | $6.37 |
| Indicator | GDHG | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 50.88 |
| Support Level | $1.84 | $3.42 |
| Resistance Level | $2.20 | $4.70 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 12.96 | 31.80 |
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.